Data protection Impressum

R&D

Business environment

Switzerland re-associates to Horizon Europe, Euratom and Digital Europe

11 November 2025

Supported by Innosuisse, CSEM spin-off CCRAFT is expanding its TFLN foundry to meet growing global demand for high-performance chips powering AI and data centers.

CCRAFT invests EUR 2.7 million to scale up photonic chip production in Neuchâtel

10 November 2025

Despite growing global trade tensions, Switzerland maintains its leadership in digital competitiveness, ahead of the US and Singapore.

Switzerland tops IMD’s 2025 Digital Competitiveness Ranking

10 November 2025

A world-class ecosystem where research, education, and industry converge to shape the future of sustainable production.

Fribourg, Switzerland’s hub for digital manufacturing

Neurotechnology company ONWARD Medical extends its cash runway through 2026 and prepares to expand commercialization and clinical development of its ARC Therapy systems.

ONWARD Medical raises over EUR 50 million to advance spinal cord therapies

27 October 2025

Vaud-based FemTech company Aspivix begins commercial rollout in Southern California and New York following strong clinical validation and growing U.S. demand.

Aspivix launches its breakthrough Carevix device in the United States

21 October 2025

Lausanne-based biotech ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.

ADC Therapeutics raises USD 60 million to strengthen oncology portfolio

21 October 2025

AI start-up General Intuition, based in Geneva and New York, has secured USD 134 million to develop spatially intelligent agents bridging gaming, robotics, and real-world systems.

General Intuition raises USD 134 million to advance AI spatial intelligence

20 October 2025

Agtech pioneer Ecorobotix secures USD 150 million to advance its Plant-by-Plant™ AI technology and unveil new innovation at Agritechnica.

Ecorobotix raises USD 150 million to accelerate AI-powered precision farming

13 October 2025

HemostOD has raised CHF 4.3 million in a Seed-extension round to accelerate the industrialization of its donor-free, off-the-shelf human blood platelets. The new funding marks a key milestone for the EPFL spin-off as it transitions from proof-of-concept to large-scale manufacturing.

HemostOD raises CHF 4.3 million to scale production of universal blood platelets

6 October 2025

1 2 3 4 5 … 16